Introduction {#sec1_1}
============

Very low birth weight (VLBW) infants commonly receive one or more red blood cell (RBC) transfusions during their first months of life \[[@B1]\]. In the majority of preterm infants, anemia is a result of multiple factors which include iatrogenic blood loss, inadequate RBC production, shorter RBC lifespan, insufficient iron stores, and rapid growth \[[@B2],[@B3],[@B4]\].

Recombinant human erythropoietin (r-HuEPO) therapy has been suggested as an alternative to RBC transfusion in the treatment of neonatal anemia. Although meta-analysis of controlled clinical studies has shown some benefit in the prevention of RBC transfusions even in extremely low birth weight infants (\<1,000 g) \[[@B5]\], treatment of anemia of prematurity (AOP) with r-HuEPO remains controversial \[[@B6],[@B7],[@B8]\]. This controversy has in part focused on conflicting strategies concerning what constitutes optimal iron supplementation during r-HuEPO treatment of anemic infants, i.e. identification of an r-HuEPO and iron-dosing schedule that provides adequate available iron to meet the needs of accelerated erythropoiesis while avoiding the risk of iron toxicity.

Unfortunately, characterization of iron-deficient states in infants is challenging. In addition to traditional parameters such as complete blood countand biochemical markers of iron metabolism, e.g., serum transferrin, transferrin saturation and serum ferritin, more recent parameters used in defining iron status and iron-deficient states include zinc erythrocyte protoporphyrin, soluble transferrin receptor (sTfR), and the ferritin index (FI) \[[@B9]\]. Zinc erythrocyte protoporphyrin is non-specific since its levels increase either when erythropoiesis is stimulated or when early functional iron deficiency (FID) is present. The interpretation of both sTfR and the FI is useful in the evaluation of iron status and erythropoietic activity as shown by Dimitriou et al. \[[@B9]\] in children and neonates. High sTfR levels indicate increased iron demand when iron stores are being depleted. Consequently the measurement of sTfR is helpful for investigating the pathophysiology of anemia by allowing the evaluation of the adequacy of marrow proliferative capacity and the erythropoietic response to various therapies \[[@B10]\].

Recently, the combination of hemoglobin content of reticulocytes (CHr), an early indicator of iron demand, and FI have been investigated by Thomas et al. \[[@B11], [@B12]\] as promising diagnostic tools for classifying and monitoring of iron deficiency in the anemia of chronic disease (ACD) in adult cancer patients. Thomas et al. \[[@B11]\] speculated that the diagnostic plot might also be a useful tool in assessing iron status in a broad spectrum of other anemias, including classical iron deficiency, end-stage renal failure and anemia of infection and inflammation. These investigators have devised a promising method for describing the relationship of FID (represented by CHr) to the availability of iron for erythropoiesis (represented by FI). These authors used a plot of these two variables to describe this relationship. Doing so offers the advantage of classifying iron deficiency into four discrete states (fig. [1](#F1){ref-type="fig"}): quadrant 1 (Q1) indicates full or replete iron stores, quadrant 2 (Q2) indicates unsatisfactory iron stores prior to iron-deficient erythropoiesis -- latent iron deficiency, quadrant 3 (Q3) indicates depletion of iron storages and decreased hemoglobinization of red cells -- iron deficiency anemia, and quadrant 4 (Q4) indicates full or replete iron stores but inappropriate iron metabolism -- FID. This plot offers the potential for monitoring erythropoietic activity, FID and the adequacy of iron availability for EPO-stimulated RBC production.

The aim of the study was to apply the diagnostic plot to the results of a previous study of r-HuEPO and iron-treated VLBW infants to assess whether this diagnostic tool is suitable for differentiating iron-deficient stages in AOP \[[@B3]\]. We hypothesized that the information derived has potential for being useful in therapeutic decision-making regarding the need for iron replacement and/or r-HuEPO therapy in anemic infants.

Methods {#sec1_2}
=======

Participants and Study Design {#sec2_1}
-----------------------------

Using the diagnostic plot to assess iron status relative to r-HuEPO and iron therapy, we retrospectively analyzed previously described data from a randomized controlled trial from clinically stable VLBW infants \<31 weeks of gestation and \<1,300 g birth weight \[[@B3]\].

In brief, inclusion criteria postnatal age \>1 week, hematocrit \>30%, phlebotomy loss averaging \<1.0 ml/day over the previous 3 days, enteral caloric intake \>20 kcal/kg/day and stable respiratory status defined as mean oxygen saturation \>90% in a fraction of inspired oxygen ≤0.40 for \>48 h regardless of ventilation. Infants excluded were those who received RBC transfusions 3 days before study entry or during the study, those with an active, culture-proven infection, a major malformation, electroencephalographic-proven seizures, hypertension, intraventricular hemorrhage ≥ grade III, immune hemolytic disease, necrotizing enterocolitis, or surgery. Among the study participants who began the study, 3 infants with sepsis or sepsis-like episodes, 2 with necrotizing enterocolitis, 2 who received RBC transfusions were excluded.

There were no statistical differences among the three study groups for common neonatal morbidities including respiratory distress syndrome (p = 0.65), bronchopulmonary dysplasia (oxygen dependency at 36 weeks of postconceptional age; p = 0.31), patent ductus arteriosus (p = 0.60) and retinopathy of prematurity (p = 0.32). There were also no significant differences identified among the three study groups for birth weight or in age, body weight, or phlebotomy loss at the prior to and during the treatment period (table [1](#T1){ref-type="table"}).

The 21-day study consisted of a 3-day run-in baseline period during which all subjects received 9 mg/kg/day of iron polymaltose complex (IPC; Ferrum Hausmann Syrup, Vifor International, St. Gallen, Switzerland). To remain in the study, subjects were not allowed to receive treatment with RBC transfusion. Study participants were randomized to receive 18 days of oral iron alone (group 1: oral iron; control group), r-HuEPO + oral iron (group 2: EPO + oral iron), or r-HuEPO + intravenous (IV) iron (group 3: EPO + IV iron) treatment beginning after a 3-day run-in period (table [2](#T2){ref-type="table"}).

Analytical Procedures {#sec2_2}
---------------------

Hematological parameters and the iron status (sTfR, ferritin) were determined on peripheral venous or arterial blood drawn on treatment days −3, 0, 4, 11, and 18. Hematological parameters were analyzed immediately. Serum and plasma were aliquoted and stored at −80°C for later analysis. Blood counts, reticulocyte counts, RBC and CHr indices were performed on fresh whole blood samples by flow cytometry (Technicon H.3 Autoanalyzer, Bayer Austria GmbH, Vienna, Austria). Ferritin was determined by a radioimmunoassay (Bio-Rad Quantimmune Ferritin IRMA, Bio-Rad Diagnostics Group, Hercules, Calif., USA). Transferrin was measured by an antigen-antibody turbidimetric method using rabbit human transferrin antiserum (Boehringer Mannheim, Indianapolis, Ind., USA). sTfR concentration was determined by an ELISA (Ramco Laboratories, Inc., Houston, Tex., USA). The FI was calculated using the following equation: sTfR \[mg/l\]/log ferritin \[μg/l\] \[[@B9]\].

Statistical Analyses {#sec2_3}
--------------------

Within-group comparisons were performed by paired-samples t test (two-tailed). Between-group comparisons were performed by independent-samples t test and ANOVA with Bonferroni posthoc multiple comparisons test for normal distributed data or Mann-Whitney U test for non-parametric sample distribution. Results are expressed as mean ± SEM. p \< 0.05 was considered statistically significant. Calculations were done with SPSS 14.0 (SPSS, Inc., Chicago, Ill., USA).

Results {#sec1_3}
=======

The age of subjects at study entry was 23 ± 2.9 days. Demographic and clinical features of the three study groups including gestational age and birth weight have been described previously and did not differ among the three groups at treatment day −3 or baseline. On day 0, none of the hematological or serological parameters demonstrated significance between group differences (table [3](#T3){ref-type="table"}) \[[@B3]\].

As anticipated, subsequent hematological and serological parameters demonstrated significant differences among the groups according to their therapeutic assignment (fig. [2a--c](#F2){ref-type="fig"}). Posttreatment changes in sTfR concentration were significantly higher in group 2 (EPO + oral iron) and group 3 (EPO + IV iron) compared to group 1 (oral iron; control group) (p \< 0.01; fig. [2a](#F2){ref-type="fig"}). The sTfR values increased significantly from baseline in both EPO groups on days 11 and 18 compared to the control group. Similarly, there was a posttreatment increase in the FI for both EPO groups starting at day 11 (p \< 0.05) compared to the control group (fig. [2b](#F2){ref-type="fig"}). A significant increase in CHr occurred at day 18 (p \< 0.05) in group 2, while in group 3 only a trend toward higher CHr values was observed which did not quite achieve statistical significance (p = 0.059) (fig. [2c](#F2){ref-type="fig"}).

Beginning on treatment day −3 and continuing to day 18 at the end of treatment, serial iron status laboratory data for each group were plotted (CHr vs. FI; fig. [3](#F3){ref-type="fig"}) according to the method of Thomas et al. \[[@B11]\]. As the study period progressed, the pattern of laboratory findings of group 1 infants differed significantly in the course of CHr and FI in comparison to both r-HuEPO-treated groups. For group 1 infants, CHr by the end of study declined into Q4, the quadrant is indicative of functional iron-deficient anemia, e.g., for ACD. In contrast, the two r-HuEPO-treated groups moved to the right, i.e. an increase in FI was observed. Although the courses of group 2 and group 3 paralleled one another over time beginning with the initiation of r-HuEPO treatment, on day 18, group 2 infants (EPO and oral iron) ended up in Q2 (latent iron deficiency) while group 3 IV EPO + IV iron-treated infants ended in Q3 (iron-deficient anemia).

Discussion {#sec1_4}
==========

The aim of the present study was to examine the clinical utility of using a diagnostic plot of Thomas et al. \[[@B11]\] to assess iron availability for erythropoiesis in VLBW infants with AOP as an informative tool for clinicians. The data analyzed were derived from a previous study of VLBW premature infants treated with two different r-HuEPO and iron-dosing regimens used in the treatment of AOP. This diagnostic plot utilizes two sensitive and specific parameters of the adequacy of iron for erythropoiesis for the x- and y-axes: FI and CHr. The CHr and the FI were used as the key hematological indicators for the intensity of the demand for iron and the adequacy of iron supply, respectively. The plot was used to identify the initial and subsequent erythropoietic and iron status of the three study groups that differed in the r-HuEPO and oral and parenteral iron supplementation each received. CHr has been used in the diagnosis of different iron-deficient states and in the response to iron and/or r-HuEPO treatment \[[@B11],[@B13],[@B14],[@B15],[@B16],[@B17]\]. Importantly, CHr provides a direct assessment of the incorporation of iron into erythrocyte hemoglobin and thus serves as a direct indicator of the recent functional availability of iron for the erythron \[[@B13], [@B18]\]. sTfR and zinc erythrocyte protoporphyrin were proposed as useful indicators for iron deficiency \[[@B19]\], because both parameters are directly associated with erythropoietic activity \[[@B10], [@B20], [@B21]\]. Both have therefore been used to help identifying iron deficiency states in children \[[@B9], [@B22], [@B23]\]. The acute-phase reactant, ferritin, has primarily been used as an indicator of iron storage \[[@B24],[@B25],[@B26]\]. In the absence of inflammatory disease, the sTfR to ferritin ratio (FI) is inversely correlated with iron stores in various anemic states, including the ACD and FID \[[@B11]\].

In the previous study from which the present data were derived, we investigated the efficacy and safety of high doses of EPO/iron therapy on the AOP \[[@B3]\]. In our application of the diagnostic plot of Thomas et al. \[[@B11]\] to the present data beginning on day −3, all three groups started in the upper left quadrant (Q1) of the plot (fig. [3](#F3){ref-type="fig"}), i.e. indicating that baseline iron status of all three groups were adequate relative to their erythropoietic demand. We speculate that the control group became increasingly anemic as a result of multiple factors impacting iron status including: (1) low endogenous EPO production, (2) diminished iron stores as a result of rapid growth, and (3) on going phlebotomy loss. We further speculated that the later two of these contributed to the decrease of CHr observed in the control group despite receiving oral iron supplementation.

Without administration of EPO, the course of the control group fell into the lower left quadrant (Q4) of the diagnostic plot and remained there until the end of the treatment period on day 18. Q4 is characteristic of anemic conditions associated with FID/ACD. These results suggest that the group 1 control subjects receiving oral iron supplementation alone experienced both r-HuEPO and iron deficiency by the end of the study. This unanticipated finding that control group infants moved from their initial position in iron sufficient Q1 to their final position at the end of the study in Q4, characteristic of anemic conditions associated with FID/ACD, is consistent with the findings of Thomas et al. \[[@B11]\]. On this point, we speculate that because the control group did not receive r-HuEPO treatment, iron was not incorporated in adequate amounts by reticulocytes. As a result, mean CHr values for control subjects fell below the 28 pg cutoff value for Q4. Thus, although iron stores were replete based on ferritin at treatment day 18 \>200 μl/l and a FI \<1.5, complete hemoglobinization did not occur. As such, treatment with r-HuEPO and additional iron supplementation might be considered as possible therapeutic considerations.

In contrast to the control group, both r-HuEPO-treated groups had moved into quadrant Q2 by treatment day 11. This can be interpreted as a successful response to the r-HuEPO therapy with a pronounced stimulation of erythropoiesis by the second week of treatment. No significant increase in CHr was observed in the EPO + IV iron group (p = 0.059) by day 18, while in the EPO + oral iron group a slight, but significant, increase in CHr was observed compared to the control group (p \< 0.05). Based on our diagnostic plot data and the recent review of iron supplementation in preterm infants by of Ridley et al. \[[@B27]\], it can be hypothesized that oral iron supplementation together with EPO therapy is adequate clinical therapy for preterm infants during their period of AOP which is in accordance with the considerations of Ridley et al. \[[@B27]\]. By day 18, the course of group 2 ended in Q2, reflecting a latent iron deficiency. In contrast, the course of group 3 ended in Q3, indicative of classic iron deficiency anemia. Additional trials are needed to assess whether r-HuEPO administration might be stopped at this point and if iron therapy (oral and/or IV iron) alone is sufficient as a therapeutic intervention for patients entering Q2 or Q4 of the diagnostic plot.

The diagnostic plot has served as a clinically useful tool in evaluating iron status of patients with renal anemia in which CHr provides helpful information regarding FID in dialysis patients receiving erythropoiesis-stimulating agents \[[@B28]\]. The diagnostic plot also appears helpful in monitoring iron therapy in cancer-related anemia \[[@B11]\]. Treatment of preterm infants with EPO and iron is one therapeutic approach for AOP exacerbated by phlebotomy (and therefore iron) loss. The diagnostic plot might also be helpful as a supporting diagnostic tool for clinicians seeking to identify the optimal r-HuEPO and iron-dosing regimens. The influence of supplementation with vitamin B~12~ and folic acid with or without r-HuEPO treatment and with IV iron to reduce the need for RBC transfusion \[[@B29]\] is another example of a clinical situation that would be of interest to apply the diagnostic plot to determine if a positive effect in the stimulation of erythropoiesis is observed. A clinical study by Worthington-White et al. \[[@B30]\] indicated that premature infants require additionally vitamin B~12~ and folate, and it could be shown that the severity of anemia was reduced. In their study, infants treated with vitamin B~12~ alone or combined with folate had higher hemoglobin values than the untreated (p \< 0.0005) or solely folate-treated (p \< 0.01) groups. In future studies, it will be important to include untreated infants starting at birth when both ferritin and sTfR levels are normally (i.e., in the absence of r-HuEPO and IV iron treatment and before receiving RBC transfusions) at their highest.

Conclusion {#sec1_5}
==========

Our results indicate that the diagnostic plot developed by Thomas et al. \[[@B11]\] offers promise as a useful tool for assessing iron status in anemic preterm infants. In its reliance on laboratory determinations performed in most hospital laboratories, the diagnostic plot has the potential for providing a readily available, real-time indicator of iron status. This has particular relevance for anemic, rapidly growing low birth weight infants during treatment with erythropoiesis-stimulating factors which result in different degrees of iron demand for hemoglobin synthesis. Additional studies carried out in a robust spectrum of clinical circumstances and other neonatal patient groups are needed before the clinical utility of this new diagnostic procedure can be unequivocally relied on.
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![Diagnostic plot for identifying the different erythropoietic states with therapeutical implications for the treatment of different phases of iron deficiency adapted from Thomas et al. \[[@B11]\]. ^a^Therapeutic implications for the treatment of different phases of iron deficiency according to Thomas et al. \[[@B11]\]](neo-0095-0164-g01){#F1}

![Change in sTfR (a), ferritin index (b) and CHr (c) during the treatment by study group. Data are shown as mean ± SEM. Post hoc statistical significance compared with group 1 is indicated by the asterisk(s): \* p \< 0.05; \*\* p \< 0.01; ns = not significant.](neo-0095-0164-g02){#F2}

![Diagnostic plot for identifying the different erythropoietic states. The course of each group is plotted from the 3-day run-in baseline period (day = −3) through the start of treatment (day = 0) continuing on to the end of treatment (day = 18). The x-axis represents the biochemical indicators for iron supply (sTfR/log ferritin, i.e., ferritin index) and the y-axis represents the hematological indicator for iron demand by erythropoiesis (CHr). Q1-4 indicates quadrants 1 to 4.](neo-0095-0164-g03){#F3}

###### 

Clinical data at birth, start of treatment and during treatment

  Study group                    Oral iron    EPO + oral iron   EPO + IV iron   p value
  ------------------------------ ------------ ----------------- --------------- ---------
  At birth                                                                      
   Weight                        1,021±84\*   923±74            1,093±66        0.28
  At start of treatment                                                         
   Age, days                     27.2±4.5     25.1±3.3          23.3±2.9        0.75
   Weight                        1,281±74     1,095±83          1,266±81        0.20
   Phlebotomy loss, ml/kg        16.5±5.4     16.3±3.8          10.6±2.0        0.49
  During treatment                                                              
   Caloric intake, kcal/kg/day   111±3.9      109±4.4           106±3.6         0.69
   Weight gain, g/kg/day         15.8± 1.4    15.1±0.9          14.0±0.7        0.47
   Weight at study exit, g       1,700±87     1,441±111         1,636±102       0.19
   Phlebotomy loss, ml/kg        5.9±0.3      8.8± 1.2          6.3±0.7         0.05

\* Mean±SEM. All between-group comparisons demonstrated no statistically significant differences.

###### 

Study treatment groups

  Treatment modality     Group 1 oral iron   Group 2 EPO + oral iron   Group 3 EPO + oral + IV iron
  ---------------------- ------------------- ------------------------- ------------------------------
  Oral iron, mg/kg/day   9                   9                         9
  IV iron, mg/kg/day     --                  --                        2
  EPO, U/kg/day          --                  300                       300

###### 

Comparison of laboratory data at the start (day 0) and the end of treatment (day 18).

                   Day   Oral iron (n = 9)   EPO + oral iron (n = 10)   EPO + IV iron (n = 10)   ANOVA p value
  ---------------- ----- ------------------- -------------------------- ------------------------ -----------------------------------------------------------------------------
  sTfR, mg/l       0     2.32±0.41           2.19±0.35                  1.76±0.13                NS
                   18    2.59±0.57           5.57±0.53                  6.69±0.71                \<0.01[^a^](#T3F1){ref-type="table-fn"}
  Ferritin, μg/l   0     309.8±32.1          380.9±72.3                 352.4±55.4               NS
                   18    171.2±35.6          233.1±43.0                 852.1± 167.5             \<0.01 [^b^](#T3F2){ref-type="table-fn"}, [^c^](#T3F3){ref-type="table-fn"}
  Ferritin index   0     0.95±0.17           0.89±0.16                  0.71±0.06                NS
                   18    1.21±0.27           2.50±0.32                  2.34±0.24                \<0.05[^a^](#T3F1){ref-type="table-fn"}
  CHr, pg          0     27.6±0.5            28.0±0.6                   28.6±0.8                 NS
                   18    26.6±0.3            28.8±0.6                   27.5±0.4                 \<0.05[^d^](#T3F4){ref-type="table-fn"}
  Hb, g/l          0     112±3               117±8                      115±5                    NS
                   18    92±3                102±7                      113±6                    \<0.05[^a^](#T3F1){ref-type="table-fn"}

Values shown are mean±SEM. NS = Not significant.

EPO + IV iron group and EPO + oral iron group compared with the oral iron group.

EPO + IV iron group compared with the oral iron group.

EPO + IV iron group compared with EPO + oral iron group.

EPO + oral iron group compared with the oral iron group.
